

Marina Pajic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4249392/publications.pdf>

Version: 2024-02-01

143
papers

25,610
citations

22153

59
h-index

9861

141
g-index

276
all docs

276
docs citations

276
times ranked

40546
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 1072-1090.	4.6	5
2	Annexin A6 and NPC1 regulate LDL-inducible cell migration and distribution of focal adhesions. <i>Scientific Reports</i> , 2022, 12, 596.	3.3	11
3	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	1.3	90
4	Ex vivo culture of intact human patient derived pancreatic tumour tissue. <i>Scientific Reports</i> , 2021, 11, 1944.	3.3	27
5	Breaking the cycle: Targeting of NDRG1 to inhibit bidirectional oncogenic cross-talk between pancreatic cancer and stroma. <i>FASEB Journal</i> , 2021, 35, e21347.	0.5	23
6	The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis. <i>Faculty Reviews</i> , 2021, 10, 4.	3.9	12
7	Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. <i>Cell</i> , 2021, 184, 1330-1347.e13.	28.9	203
8	Interfacial Curvature in Confined Coculture Directs Stromal Cell Activity with Spatial Corraling of Pancreatic Cancer Cells. <i>Advanced Biology</i> , 2021, 5, e2000525.	2.5	8
9	Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype. <i>Cell Reports</i> , 2021, 35, 108945.	6.4	38
10	Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. <i>Nature Chemical Biology</i> , 2021, 17, 776-783.	8.0	17
11	Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity. <i>Nature Communications</i> , 2021, 12, 2622.	12.8	34
12	A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. <i>ELife</i> , 2021, 10, .	6.0	14
13	Single cell transcriptome atlas of mouse mammary epithelial cells across development. <i>Breast Cancer Research</i> , 2021, 23, 69.	5.0	26
14	Oral administration of bovine milk-derived extracellular vesicles induces senescence in the primary tumor but accelerates cancer metastasis. <i>Nature Communications</i> , 2021, 12, 3950.	12.8	70
15	Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. <i>Molecular Oncology</i> , 2021, 15, 3242-3255.	4.6	52
16	Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. <i>Cancers</i> , 2021, 13, 3481.	3.7	13
17	TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2021, 40, 6007-6022.	5.9	10
18	Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging. <i>Cell Reports</i> , 2021, 36, 109689.	6.4	12

#	ARTICLE	IF	CITATIONS
19	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. <i>Science Advances</i> , 2021, 7, eabh0363.	10.3	23
20	Quantifying and visualising the nuances of cellular dynamics in vivo using intravital imaging. <i>Current Opinion in Cell Biology</i> , 2021, 72, 41-53.	5.4	7
21	Ral GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes. <i>ELife</i> , 2021, 10, .	6.0	70
22	Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 750852.	2.8	6
23	Shedding new light on RhoA signalling as a drug target <i>in vivo</i> using a novel RhoA-FRET biosensor mouse. <i>Small GTPases</i> , 2020, 11, 240-247.	1.6	5
24	Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. <i>Small GTPases</i> , 2020, 11, 45-52.	1.6	38
25	The Mini-Organ: A rapid high-throughput 3D coculture organotypic assay for oncology screening and drug development. <i>Cancer Reports</i> , 2020, 3, e1209.	1.4	8
26	MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. <i>Oncogene</i> , 2020, 39, 1821-1829.	5.9	17
27	Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. <i>Cancer Letters</i> , 2020, 472, 8-18.	7.2	31
28	Fluids and their mechanics in tumour transit: shaping metastasis. <i>Nature Reviews Cancer</i> , 2020, 20, 107-124.	28.4	232
29	Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. <i>EMBO Journal</i> , 2020, 39, e104063.	7.8	224
30	Nuclear F-actin counteracts nuclear deformation and promotes fork repair during replication stress. <i>Nature Cell Biology</i> , 2020, 22, 1460-1470.	10.3	87
31	PtdIns(3,4,5)P3-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28056-28067.	7.1	11
32	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	6.4	78
33	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. <i>Science</i> , 2020, 368, 1127-1131.	12.6	83
34	Targeting genetically-tuned CAFs in pancreatic cancer <i>via</i> perlecan manipulation. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 171-174.	3.4	4
35	PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 24.	2.0	36
36	Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. <i>Theranostics</i> , 2020, 10, 4116-4133.	10.0	23

#	ARTICLE	IF	CITATIONS
37	Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1223, 99-127.	1.6	17
38	ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism. <i>Nature Cell Biology</i> , 2020, 22, 882-895.	10.3	47
39	CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. <i>Nature Communications</i> , 2019, 10, 3637.	12.8	170
40	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. <i>FEBS Journal</i> , 2019, 286, 3510-3539.	4.7	33
41	CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. <i>Trends in Cancer</i> , 2019, 5, 724-741.	7.4	214
42	Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 43.	5.0	33
43	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. <i>Gut</i> , 2019, 68, 742-758.	12.1	68
44	PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 3353-3364.	0.0	3
45	Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. <i>Cancer Research</i> , 2018, 78, 3321-3336.	0.9	64
46	Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism. <i>Cell Metabolism</i> , 2018, 27, 1096-1110.e5.	16.2	309
47	Molecular mobility and activity in an intravital imaging setting – implications for cancer progression and targeting. <i>Journal of Cell Science</i> , 2018, 131, .	2.0	32
48	133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling. <i>Nature Communications</i> , 2018, 9, 254.	12.8	55
49	Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. <i>Gastroenterology</i> , 2018, 154, 820-838.	1.3	173
50	BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma. <i>Pathology</i> , 2018, 50, 345-348.	0.6	8
51	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018, 67, 2142-2155.	12.1	100
52	miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. <i>Cancer Research</i> , 2018, 78, 501-515.	0.9	105
53	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 103.	2.5	7
54	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. <i>Pharmacological Research</i> , 2018, 134, 166-178.	7.1	8

#	ARTICLE	IF	CITATIONS
55	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 2897.	12.8	293
56	ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. <i>Human Pathology</i> , 2018, 82, 249-257.	2.0	42
57	Removing physiological motion from intravital and clinical functional imaging data. <i>ELife</i> , 2018, 7, .	6.0	34
58	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. <i>Oncogene</i> , 2018, 37, 4518-4533.	5.9	45
59	Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. <i>Cell Reports</i> , 2018, 23, 3312-3326.	6.4	61
60	Recent advances in understanding the complexities of metastasis. <i>F1000Research</i> , 2018, 7, 1169.	1.6	45
61	Recent advances in understanding the complexities of metastasis. <i>F1000Research</i> , 2018, 7, 1169.	1.6	75
62	Annexin A6 is a multifunctional scaffold in cell motility. <i>Cell Adhesion and Migration</i> , 2017, 11, 288-304.	2.7	53
63	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. <i>Gut</i> , 2017, 66, 1665-1676.	12.1	212
64	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
65	Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. <i>Methods</i> , 2017, 128, 78-94.	3.8	37
66	Mitochondrial mutations and metabolic adaptation in pancreatic cancer. <i>Cancer & Metabolism</i> , 2017, 5, 2.	5.0	51
67	Effective modulation of stromal signaling through ROCK inhibition: Is it all in the timing?. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1333973.	0.7	4
68	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	208
69	A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts. <i>Cell Reports</i> , 2017, 21, 274-288.	6.4	83
70	Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. <i>Clinical Cancer Research</i> , 2017, 23, 7020-7033.	7.0	20
71	Lost in translation: returning germline genetic results in genome-scale cancer research. <i>Genome Medicine</i> , 2017, 9, 41.	8.2	27
72	Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	1.3	174

#	ARTICLE	IF	CITATIONS
73	Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology. <i>Scientific Reports</i> , 2017, 7, 16887.	3.3	22
74	Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. <i>Oncotarget</i> , 2017, 8, 26066-26078.	1.8	81
75	Transient targeting of the pancreatic cancer stroma as a "fine-tuned" anti-tumor and anti-metastatic therapy. <i>Oncotarget</i> , 2017, 8, 84635-84636.	1.8	2
76	Recruitment Kinetics of Tropomyosin Tpm3.1 to Actin Filament Bundles in the Cytoskeleton Is Independent of Actin Filament Kinetics. <i>PLoS ONE</i> , 2016, 11, e0168203.	2.5	12
77	Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. <i>Molecular Oncology</i> , 2016, 10, 866-878.	4.6	23
78	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. <i>Cancer Research</i> , 2016, 76, 6084-6094.	0.9	73
79	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2671-2685.	3.8	29
80	Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue. <i>Cell Reports</i> , 2016, 14, 152-167.	6.4	54
81	Annexin A6 and Late Endosomal Cholesterol Modulate Integrin Recycling and Cell Migration. <i>Journal of Biological Chemistry</i> , 2016, 291, 1320-1335.	3.4	43
82	Differential Rac1 signalling by guanine nucleotide exchange factors implicates FLII in regulating Rac1-driven cell migration. <i>Nature Communications</i> , 2016, 7, 10664.	12.8	72
83	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	27.8	2,700
84	Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression. <i>F1000Research</i> , 2016, 5, 892.	1.6	11
85	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e17.	3.9	51
86	Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion. <i>Current Biology</i> , 2015, 25, 3019-3034.	3.9	74
87	Targeting the <sc>LOX</sc> / <sc>hypoxia</sc> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <sc>LOX</sc> abrogates metastasis and enhances drug efficacy. <i>EMBO Molecular Medicine</i> , 2015, 7, 1063-1076.	6.9	223
88	High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. <i>Breast Cancer Research</i> , 2015, 17, 79.	5.0	134
89	The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2-deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. <i>International Journal of Oncology</i> , 2015, 46, 2223-2230.	3.3	17
90	A Negative Regulatory Mechanism Involving 14-3-3 Limits Signaling Downstream of ROCK to Regulate Tissue Stiffness in Epidermal Homeostasis. <i>Developmental Cell</i> , 2015, 35, 759-774.	7.0	33

#	ARTICLE	IF	CITATIONS
91	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	27.8	2,132
92	The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking. <i>Science Signaling</i> , 2015, 8, ra18.	3.6	57
93	Imaging fibrosis in pancreatic cancer using second harmonic generation. <i>Pancreatology</i> , 2015, 15, 200-201.	1.1	4
94	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPACT) Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2029-2037.	7.0	209
95	The cross-talk of LDL-cholesterol with cell motility: Insights from the Niemann Pick Type C1 mutation and altered integrin trafficking. <i>Cell Adhesion and Migration</i> , 2015, 9, 384-391.	2.7	17
96	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 483-497.	4.4	41
97	The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. <i>Small GTPases</i> , 2015, 6, 123-133.	1.6	37
98	The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis. <i>Cancer Cell</i> , 2015, 28, 155-169.	16.8	91
99	SOX9 regulates ERBB signalling in pancreatic cancer development. <i>Gut</i> , 2015, 64, 1790-1799.	12.1	71
100	FAK signaling in human cancer as a target for therapeutics. , 2015, 146, 132-149.		317
101	Clinical and pathologic features of familial pancreatic cancer. <i>Cancer</i> , 2014, 120, 3669-3675.	4.1	53
102	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. <i>International Journal of Cancer</i> , 2014, 135, 1110-1118.	5.1	192
103	Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 3187-3197.	7.0	32
104	The Rac-FRET Mouse Reveals Tight Spatiotemporal Control of Rac Activity in Primary Cells and Tissues. <i>Cell Reports</i> , 2014, 6, 1153-1164.	6.4	79
105	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. <i>Nature Reviews Cancer</i> , 2014, 14, 314-328.	28.4	134
106	Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. <i>Carcinogenesis</i> , 2014, 35, 1671-1679.	2.8	123
107	Returning individual research results for genome sequences of pancreatic cancer. <i>Genome Medicine</i> , 2014, 6, 42.	8.2	25
108	An analysis of reported motivational orientation in students undertaking doctoral studies in the biomedical sciences. <i>BMC Medical Education</i> , 2014, 14, 38.	2.4	6

#	ARTICLE	IF	CITATIONS
109	Cholesterol Regulates Syntaxin 6 Trafficking at trans-Golgi Network Endosomal Boundaries. <i>Cell Reports</i> , 2014, 7, 883-897.	6.4	104
110	Personalising pancreas cancer treatment: When tissue is the issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7849.	3.3	22
111	Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15209-e15209.	1.6	0
112	Understanding pancreatic cancer genomes. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 549-556.	2.6	31
113	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	27.8	8,060
114	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , 2013, 5, 78.	8.2	97
115	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.	1.6	142
116	Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 4674-4686.	0.9	111
117	Advanced intravital subcellular imaging reveals vital three-dimensional signalling events driving cancer cell behaviour and drug responses in live tissue. <i>FEBS Journal</i> , 2013, 280, 5177-5197.	4.7	10
118	Peer relationships and the biomedical doctorate: a key component of the contemporary learning environment. <i>Journal of Higher Education Policy and Management</i> , 2013, 35, 370-385.	2.3	9
119	Somatic Point Mutation Calling in Low Cellularity Tumors. <i>PLoS ONE</i> , 2013, 8, e74380.	2.5	67
120	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. <i>Cancer Research</i> , 2012, 72, 2350-2361.	0.9	48
121	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	27.8	1,741
122	qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles. <i>PLoS ONE</i> , 2012, 7, e45835.	2.5	92
123	Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction. <i>PLoS ONE</i> , 2011, 6, e26088.	2.5	55
124	ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 270-279.	1.5	23
125	Organotypic Collagen I Assay: A Malleable Platform to Assess Cell Behaviour in a 3-Dimensional Context. <i>Journal of Visualized Experiments</i> , 2011, , e3089.	0.3	66
126	Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β -Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth. <i>Cancer Cell</i> , 2011, 19, 776-791.	16.8	477

#	ARTICLE	IF	CITATIONS
127	Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. <i>Human Genetics</i> , 2011, 130, 93-101.	3.8	13
128	Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. <i>Cancer Research</i> , 2011, 71, 747-757.	0.9	127
129	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan. <i>Cancer Research</i> , 2010, 70, 1700-1710.	0.9	76
130	Quantitative <i>In vivo</i> Imaging of the Effects of Inhibiting Integrin Signaling via Src and FAK on Cancer Cell Movement: Effects on E-cadherin Dynamics. <i>Cancer Research</i> , 2010, 70, 9413-9422.	0.9	122
131	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 246-251.	7.1	530
132	Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells <i>in vivo</i> . <i>Cell Cycle</i> , 2010, 9, 3804-3815.	2.6	24
133	Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2010, 139, 292-303.	1.3	123
134	Moderate Increase in <i>Mdr1a/1b</i> Expression Causes <i>In vivo</i> Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer. <i>Cancer Research</i> , 2009, 69, 6396-6404.	0.9	88
135	Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. <i>Cancer Research</i> , 2009, 69, 6573-6580.	0.9	100
136	Aberrant Expression of Cortactin in Head and Neck Squamous Cell Carcinoma Cells Is Associated with Enhanced Cell Proliferation and Resistance to the Epidermal Growth Factor Receptor Inhibitor Gefitinib. <i>Cancer Research</i> , 2007, 67, 9304-9314.	0.9	87
137	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12117-12122.	7.1	279
138	Nucleus Pulposus Cellular Longevity by Telomerase Gene Therapy. <i>Spine</i> , 2007, 32, 1188-1196.	2.0	38
139	Distinction at the leading edge of the cell. <i>BioEssays</i> , 2005, 27, 349-352.	2.5	3
140	Cortactin Overexpression Inhibits Ligand-Induced Down-regulation of the Epidermal Growth Factor Receptor. <i>Cancer Research</i> , 2005, 65, 3273-3280.	0.9	77
141	The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. <i>Cancer Letters</i> , 2005, 228, 241-246.	7.2	30
142	Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. <i>Current Biology</i> , 2001, 11, 1836-1846.	3.9	175
143	Perceived Assessment Requirements in the Contemporary Biomedical Doctorate: A Case-Study from a Research Intensive Australian University. <i>International Journal of Doctoral Studies</i> , 0, 8, 105-120.	1.0	2